Your session is about to expire
← Back to Search
Mesenchymal Stem Cell Therapy
Descartes-25 for Multiple Myeloma
Phase 1 & 2
Recruiting
Research Sponsored by Cartesian Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosed with active R/RMM, who have failed 2 lines of treatment
18 years and older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Study Summary
This trial is testing a new stem cell treatment for patients with a certain type of blood cancer that has come back or hasn't responded to other treatments.
Who is the study for?
This trial is for adults with active Relapsed/Refractory Multiple Myeloma (R/RMM) who have not responded to at least two prior treatments and still show measurable signs of the disease. It's not open to patients with active plasma cell leukemia.Check my eligibility
What is being tested?
The study is testing Descartes-25, a Mesenchymal Stem Cell product that releases a special protein aimed at treating R/RMM. The trial will gradually increase doses to find safe levels and see how well it works.See study design
What are the potential side effects?
Potential side effects are not specified but may include typical reactions related to stem cell therapies such as immune responses, infusion-related symptoms, or complications from proteins produced by the cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have relapsed or refractory multiple myeloma and failed two treatments.
Select...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Maximum Tolerated Dose
Secondary outcome measures
Median Duration of Response
Overall Response Rate according to the IMWG response criteria
Trial Design
4Treatment groups
Experimental Treatment
Group I: Arm 4: Dose ExpansionExperimental Treatment1 Intervention
In Arm 2, the MTD established in Arm 1 will be administered for 3 28-day cycles to further evaluate the product's safety and preliminary efficacy.
Group II: Arm 3: Dose Level 3Experimental Treatment1 Intervention
Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
Group III: Arm 2: Dose Level 2Experimental Treatment1 Intervention
Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
Group IV: Arm 1: Dose Level 1Experimental Treatment1 Intervention
Minimum of 3 patients per Dose Level will be treated sequentially with once weekly infusions for 3 weeks in a 28-day cycle until the Maximum Tolerated Dose (MTD) is reached.
Find a Location
Who is running the clinical trial?
Cartesian TherapeuticsLead Sponsor
8 Previous Clinical Trials
228 Total Patients Enrolled
5 Trials studying Multiple Myeloma
138 Patients Enrolled for Multiple Myeloma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My cancer can be measured by tests.I am 18 years old or older.I have active plasma cell leukemia.I have relapsed or refractory multiple myeloma and failed two treatments.
Research Study Groups:
This trial has the following groups:- Group 1: Arm 4: Dose Expansion
- Group 2: Arm 1: Dose Level 1
- Group 3: Arm 2: Dose Level 2
- Group 4: Arm 3: Dose Level 3
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the maximum capacity for participants in this medical experiment?
"To initiate the study, Cartesian Therapeutics needs to recruit 20 patients that meet their criteria. Two major sites offering this trial are Center for Cancer and Blood Disorders in Bethesda, Maryland and Medical College of Wisconsin in Madison, Wisconsin."
Answered by AI
Are there still spots available for this clinical trial?
"Perusal of the clinicaltrials.gov website shows that this medical research is presently recruiting volunteers, having first been posted on November 25th 2021 and lastly updated on November 4th 2022."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger